Progressive MS

March 18, 2019March 19, 2019

Progressive MS Phase 2 Trial of NurOwn Stem Cell Therapy Enrolls 1st Patient

News

The first patient has been enrolled in a Phase 2 multicenter clinical trial testing the use of NurOwn cellular therapy to treat progressive multiple sclerosis (MS), BrainStorm Cell Therapeutics ... Read more

March 13, 2019March 15, 2019

Phase 2 Trial Will Assess Autologous Mesenchymal Stem Cell Therapy to Treat Progressive Forms of MS

News

The National Multiple Sclerosis Society is funding a new Phase 2 clinical trial to test the effectiveness of stem cell therapy on individuals with progressive forms of multiple sclerosis (MS), ... Read more

March 4, 2019March 4, 2019

#ACTRIMS2019 – Jeffrey Cohen, MD, is New President of ACTRIMS

News

Jeffrey Cohen, MD, director of the experimental therapeutics program at the Mellen Center for Multiple Sclerosis Treatment and Research at the Cleveland Clinic, is the newly named  president of ACTRIMS, ... Read more

February 28, 2019February 27, 2019

Breaking Down the Silos in the MS Community

Columns, Engaging Thoughts

In the research world, references to breaking down silos abound, and we’re not talking about those found on the farm. These figurative silos are where information is contained and ... Read more

February 26, 2019March 7, 2019

Cleveland Clinic Chosen for Phase 2 Trial Testing NurOwn Stem Cell Therapy in Progressive MS Patients

News

BrainStorm Cell Therapeutics announced the Cleveland Clinic is the first clinical site contracted in the United States for the Phase 2 multi-center study evaluating the company’s NurOwn mesenchymal stem cell (MSC) ... Read more

February 19, 2019February 22, 2019

Participants Sought for Clinical Trial Studying Effects of Lipoic Acid on Progressive MS

News

A clinical trial to test the effects of antioxidant treatment with lipoic acid on progressive forms of multiple sclerosis (MS) is recruiting 118 participants at seven sites in North America. ... Read more

January 21, 2019January 28, 2019

Fatigue More Common in Progressive MS Patients, Survey Shows

News

Fatigue is more prevalent among patients with progressive multiple sclerosis (MS), according to a study that surveyed patients on fatigue and factors related to it. In addition, increased fatigue ... Read more

November 21, 2018November 21, 2018

Phase 2 Trial of NurOwn Stem Cell Therapy in Progressive MS Planned for US, BrainStorm Announces

News

BrainStorm Cell Therapeutics is planning to launch a Phase 2 clinical trial in the United States to evaluate the safety and activity of its lead cell therapy candidate, NurOwn, in ... Read more

November 14, 2018November 20, 2018

Phase 3 Trial of MD1003 in Treating Progressive MS Fully Enrolled, MedDay Announces

News

A Phase 3 clinical trial intending to confirm the potential of MD1003, a high-dose biotin, in treating progressive multiple sclerosis (MS) patients is completely enrolled, MedDay Pharmaceuticals, the investigational therapy’s developer, ... Read more

September 18, 2018September 20, 2018

Ibudilast Slows Brain Shrinkage 48% in Progressive MS Patients in Phase 2 Trial; Lead Researcher Says Finding is ‘Remarkable’

News

Progressive multiple sclerosis patients — with primary or secondary progressive disease — treated with high doses of oral ibudilast in a Phase 2 clinical trial showed a 48 percent slowing in ... Read more

September 18, 2018September 18, 2018

Grant Awarded to Research New Method to Treat Cognitive Dysfunction in Progressive MS

News

The Multiple Sclerosis Society of Canada and the Multiple Sclerosis Scientific Research Foundation have awarded a $410,000 grant to fund research based on a new method for treating cognitive ... Read more

August 31, 2018September 7, 2018

Cell-free Mitochondrial DNA in Cerebrospinal Fluid of Progressive MS Patients May Point to Neurodegeneration

News

Cerebrospinal fluid of progressive multiple sclerosis (MS) patients may carry lower levels of cell-free mitochondrial DNA, according to a team of researchers who say this may be a sign ... Read more

August 2, 2018August 6, 2018

Multiple Sclerosis Patients Identify Symptoms that Worsen Quality of Life

News

Loss of health-related quality of life is caused mostly by balance problems, muscle stiffness, and depression in people with relapsing-remitting multiple sclerosis (RRMS), and for those with progressive MS, the ... Read more

June 21, 2018July 12, 2018

Webinar Focuses on Importance of Maintaining Independence for Progressive MS Patients

News

When a progressively debilitating disease like multiple sclerosis (MS) causes a patient to feel physically “wiped out” after a simple daily activity, such as a shower, it is of ... Read more

May 18, 2018May 18, 2018

Rituximab Seen as Effective and Generally Safe RRMS and PMS Treatment in Study

News

Rituximab is generally safe and effective in treating multiple sclerosis — with comparable effectiveness to Tysabri (natalizumab) in people with relapsing-remitting forms of the disease, a Swiss study reports. ... Read more

April 19, 2018April 19, 2018

#AAN2018 — Investigational Therapy Ibudilast Slows Brain Atrophy in Phase 2 Trial for Progressive MS

News

Investigational therapy ibudilast leads to a significant reduction of brain atrophy, supporting its potential to effectively treat progressive multiple sclerosis (MS), new data from a Phase 2 clinical trial show. These ... Read more

February 28, 2018February 28, 2018

Inhibiting Oxidative Stress Enzyme Reduces Nerve Cell Damage in Mice with MS, Study Shows

News

Inhibiting an oxidative stress enzyme reduced nerve cell damage and promoted the formation of new nerve cells, a multiple sclerosis study in mice showed. It also helped regenerate cells that ... Read more

February 2, 2018February 2, 2018

#ACTRIMS2018 – MediciNova Presents Positive Results from SPRINT-MS Trial Evaluating Ibudilast in Progressive MS

News

Top-line results from a clinical trial evaluating the investigational oral therapy ibudilast for progressive multiple sclerosis (MS) show that the therapy led to a significant reduction of brain atrophy ... Read more

January 8, 2018January 8, 2018

Trial of AB Science’s Progressive MS Therapy to Continue Without Additional Patient Requirement

News

A Phase 3 clinical trial evaluating AB Science’s masitinib as a treatment for progressive multiple sclerosis can continue without having to add patients, an independent review board has decided. The ... Read more

December 29, 2017December 22, 2017

Clomipramine, an Antidepressant, Shows Potential in Treating Progressive MS in Early Study

News

Clomipramine, an approved antidepressant, shows potential in treating people with progressive multiple sclerosis (MS)  — a disease form with few treatments — by protecting nerves from various processes thought ... Read more

December 15, 2017December 15, 2017

Cambridge Researcher Wins 2017 Barancik Prize for Pioneering Work on Myelin Repair

News

A University of Cambridge researcher, Robin Franklin, has been awarded the 2017 Barancik Prize for Innovation in MS Research for his work on myelin repair and as a potential ... Read more

November 14, 2017November 15, 2017

MMJ Hires Lead Investigator for Phase 2 Trials of Medicinal Cannabis to Treat Progressive MS

News

MMJ BioScience, an affiliate of medical cannabis research company MMJ International Holdings, has hired a principal investigator to lead clinical trials exploring potential therapeutic applications of cannabinoids in progressive multiple ... Read more

November 9, 2017January 4, 2018

Longevity Receives $316,000 Grant to See if Its Nerve-cell-protecting Therapy Will Work in MS

News

Longevity Biotech has received a $316,384 grant from the National MS Society to see if LBT-3627, the nerve cell-protecting therapy it has tested in Parkinson’s, can work in multiple sclerosis as well. The company designed ... Read more

October 31, 2017October 31, 2017

#MSParis2017 – Advances in Progressive and Pediatric MS Top ECTRIMS Highlights, NMSS Says

News

A giant leap in research and interest in progressive multiple sclerosis — from a few people pushing for such work to 2,000 listening to updates on it — a ... Read more

October 26, 2017October 26, 2017

#MSParis2017 – MedDay’s High-Dose Biotin, MD1003, Improves Disability in Progressive MS Patients

News

MD1003, a high-dose biotin developed by MedDay, slowed or prevented further disease progression among progressive multiple sclerosis (MS) patients in a Phase 3 clinical trial, researchers announced at the Oct. ... Read more

October 18, 2017May 21, 2018

#MSParis2017 – Progressive MS Research Among ECTRIMS Highlights, National MS Society Says

News, Ocrevus

The 7th Joint ECTRIMS-ACTRIMS Meeting, taking place in Paris this month, is one of the largest scientific conferences focused solely on multiple sclerosis (MS), and the National Multiple Sclerosis ... Read more

September 22, 2017September 25, 2017

Study Links MIF, D-DT Molecules to Progressive Multiple Sclerosis Development

News

Two molecules known to regulate cellular signaling contribute to the underlying mechanism of progressive multiple sclerosis, found a recent study conducted by investigators at Oregon Health & Science University ... Read more

September 1, 2017September 5, 2017

#MSParis2017 – MediciNova to Share Results of Ibudilast Trial in Progressive MS at October Summit

News

MediciNova will present data from its clinical trial of ibudilast in progressive multiple sclerosis at the upcoming 7th Joint ECTRIMS – ACTRIMS Meeting in Paris. ECTRIMS and ACTRIMS selected the ... Read more

May 9, 2017May 9, 2017

MedDay’s New Phase 3 Trial and Belief in Biotin’s Potential to Treat Progressive MS: An Interview with Dr. Frédéric Sedel

News

A global Phase 3 clinical trial assessing MD1003 — also known as high-dose biotin — for progressive multiple sclerosis (MS) might lead to the approval of one of the first ... Read more

March 13, 2017March 13, 2017

UMass Amherst Receives $833,000 Pentagon Grant to Create Improved MS Diagnostic Test

News

Kinesiology professor Richard van Emmerik and his colleagues at the University of Massachusetts Amherst recently received a two-year $833,000 grant from the U.S. Department of Defense to create an improved diagnostic ... Read more

February 24, 2017February 24, 2017

#ACTRIMS2017 – Sun Exposure May Lower Fatigue, Slow Disability Progression in MS

News

Spending more time in the sunshine could make people with multiple sclerosis (MS) feel more energetic, though dietary vitamin D intake’s effect is mixed, depending on what type of MS ... Read more

December 19, 2016January 2, 2017

High dose biotin protocol – my nine month update!

Columns, Faith of the Mustard Seed - a Column by Debi Wilson

Nine months ago I started the high dose biotin protocol. I did so in an effort to slow the progression of my primary progressive multiple sclerosis. This is the ... Read more

October 12, 2016October 12, 2016

Potential Therapy, Laquinimod, Shows Promise as Progressive MS Treatment in Mouse Study

News

The experimental therapy laquinimod was seen to prevent the start of harmful immune responses and to disrupt the progression of multiple sclerosis (MS) in a mouse model of the disease. This ... Read more

September 23, 2016September 23, 2016

Progressive MS Alliance Awards $18M to 3 Research Projects into Disease Treatments, Expanded Testing

News

The International Progressive Multiple Sclerosis (MS) Alliance, a worldwide group of MS organizations that support research efforts, has awarded three, four-year grants — called Collaborative Network Awards, and worth $6 ... Read more

September 19, 2016September 19, 2016

#ECTRIMS2016 – Treatment of Progressive MS May Have Delayed Result

News

There might be years-long lags in response to disease-modifying drugs in patients with progressive forms of multiple sclerosis (MS), according to a study that analyzed data from two large ... Read more

July 10, 2016

Relapsing vs Progressive Multiple Sclerosis

Recently, the U.S. Food and Drug Administration (FDA) gave priority review to a request to approve Ocrevus (ocrelizumab) as a treatment for both relapsing and primary progressive MS. But each ... Read more

June 6, 2016June 6, 2016

#CMSC16 – Novel Model of Home Care for Patients with Progressive MS Proven Beneficial, Increased Patients’ Satisfaction

News

A new model of care implemented to address the needs of patients with progressive multiple sclerosis (MS) and their caregivers has proven beneficial by reducing hospital stays, avoiding major care ... Read more

May 31, 2016October 24, 2016

MedDay Presents Phase 3 Extension Data on Potential Drug to Treat Progressive MS

News

Data from an extension phase of a Phase 3 clinical trial, given in an oral presentation by MedDay, reported that the biotin  MD1003 showed effectiveness over time as a possible treatment of non-active, progressive ... Read more

May 3, 2016May 3, 2016

Opexa’s CEO Gives Update on T-Cell Therapy at Vatican Conference

News

Opexa Therapeutics, Inc., announced that its president and chief executive officer, Neil K. Warma, recently gave a presentation on immunotherapy and its potential for treating autoimmune disorders, including multiple sclerosis, at the recent Cellular ... Read more

April 12, 2016April 12, 2016

MedDay Raises $38.5M to Finance Phase 3 Trial Targeting Progressive MS

News

MedDay SAS recently announced that it has raised €34 million, about $38.5 million, in a Series B financing round. The money will enable the company to lead a confirmatory Phase 3 ... Read more